Tenofovir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
<scene name='96/960003/Cv/3'>Tenofovir diphosphate (TNV) binding site</scene> at reverse transcriptase ([[3fkb]]). | <scene name='96/960003/Cv/3'>Tenofovir diphosphate (TNV) binding site</scene> at reverse transcriptase ([[3fkb]]). | ||
<scene name='96/960003/ | <scene name='96/960003/Tnmbindingsite/1'>Tenofovir-monophosphate (TNM) binding site</scene> at reverse transcriptase ([[3fkb]]). | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 15:28, 16 April 2023
Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. See also [1]. Tenofovir disoproxil is a prodrug that is quickly absorbed from the gut and cleaved to release tenofovir. Inside cells, tenofovir is phosphorylated to tenofovir diphosphate (which is analogous to a triphosphate, as tenofovir itself already has one phosphonate residue), the active compound that inhibits reverse transcriptase via chain termination. at reverse transcriptase (3fkb). at reverse transcriptase (3fkb).
|
| ||||||||||